Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise in recent clinical trials. Nuclease-driven genome editing provides a method in which to precisely target genetic changes to further enhance T cell function in vivo. We describe the development of a highly efficient method to genome edit both primary human CD8 and CD4 T cells by homology-directed repair at a pre-defined site of the genome. Two different homology donor templates were evaluated, representing both minor gene editing events (restriction site insertion) to mimic gene correction, or the more significant insertion of a larger gene cassette. By combining zinc finger nuclease mRNA delivery with AAV6 delivery of a homologous donor we could gene correct 41% of CCR5 or 55% of PPP1R12C (AAVS1) alleles in CD8(+) T cells and gene targeting of a GFP transgene cassette in >40% of CD8(+) and CD4(+) T cells at both the CCR5 and AAVS1 safe harbor locus, potentially providing a robust genome editing tool for T cell-based immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 2×
“Merged reads were filtered using the following criteria: the 5 and 3 ends (23 bp) must match the expected amplicon exactly, the read must not map to a different lo-cus in the target genome as determined by Bowtie2 (24) with default settings, and deletions must be 70% of the amplicon size or 70 bp long.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820 · cited 1×
“…nucleases (TALENs), and the RNA-guided clustered regularly interspaced short palindromic repeat (CRISPR) / Cas endonucleases, are a powerful class of enzymes that promote genome editing through the creation of a site-specific DNA double-strand break (DSB) at a pre-defined site in the genome (8).”
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506 · cited 1×
“Nucleic Acids Research, 2016, Vol. 44, No. 3 e30 CD8 + cytotoxic T lymphocytes (CTLs) have been proven to exhibit potent anti-tumor activity in preclinical and clinical studies (1–2 , 26– 28 ).”
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388 · cited 2×
“Furthermore, Engineered CD19-specific CD4 + T cell responses comprised at least part of the anti-tumor effects against B-cell malignance in a few of the recent successful clinical trials (26-28).”
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Self-citationTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“However, the semi-random nature of vector insertion can result in non-authentic patterns of gene expression, transgene silencing over time, or the potential to trans-activate neighboring genes leading to insertional mutagenesis events (5–7).”
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641 · cited 1×
“Previous studies utilizing plasmid or viral vectors such as IDLV to deliver the donor template demonstrated that targeted trans-gene addition can possibly be achieved in ∼ 5–7% of primary T cells (12,18).”
Self-citationKochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D. E., Maric, I., Stetler-Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2012) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,440 · cited 1×
“Furthermore, Engineered CD19-specific CD4+ T cell responses comprised at least part of the anti-tumor effects against B-cell malignance in a few of the recent successful clinical trials (26-28).”
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“CCR5 and AAVS1 homologous donor templates (12,22) were cloned into a customized plasmid pRS165 derived from pAAV-MCS (Agilent Technologies, Santa Clara, CA, USA), containing AAV2 inverted terminal repeats (ITRs), to enable packaging as AAV vectors us-ing the triple-transfection method (23).”
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357 · cited 1×
“Besides this promising anti-tumor function, genome edited CD4 + T cells have been tested as an adoptive cell therapy for HIV / AIDS (44).”
Self-citationThe Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,286 · cited 2×
“Furthermore, Engineered CD19-specific CD4 + T cell responses comprised at least part of the anti-tumor effects against B-cell malignance in a few of the recent successful clinical trials (26-28).”
An improved zinc-finger nuclease architecture for highly specific genome editing
Miller, J. C., Holmes, M. C., Wang, J., Guschin, D. Y., Lee, Y.-L., Rupniewski, I., Beausejour, C. M., Waite, A. J., Wang, N. S., Kim, K. A., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1319 · Cited by 1,051 · cited 1×
“The following FokI variants were used to construct obligate heterodimeric versions of ZFNs (19,20): EL:KK ( CCR5 ) and ELD:KKR ( AAVS1 ).”
Self-citationEstablishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999 · cited 1×
“ZFNs targeting the CCR5 and AAVS1 loci have been described previously (11,13).”
Self-citationTreatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911 · cited 1×
“In addition to classic helper function, CD4 + T cells also have cytolytic activity depending on class II-restricted recognition of tumor antigens, and have exhibited anti-tumor effects in patients with metastatic melanoma (39– 43).”
DNA Double-Strand Break Repair: All's Well that Ends Well
Wyman, C., & Kanaar, R. (2006) · Annual Review of Genetics · doi:10.1146/annurev.genet.40.110405.090451 · Cited by 803 · cited 1×
“Repair of DSBs can proceed via the non-homologous end joining (NHEJ) or homology-directed repair (HDR) pathways (9,10).”
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797 · cited 1×
“In addition to classic helper function, CD4 + T cells also have cytolytic activity depending on class II-restricted recognition of tumor antigens, and have exhibited anti-tumor effects in patients with metastatic melanoma (39– 43).”
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
Schumann, K., Lin, S., Boyer, E., Simeonov, D. R., Subramaniam, M., Gate, R. E., Haliburton, G. E., Ye, C. J., Bluestone, J. A., Doudna, J. A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1512503112 · Cited by 702 · cited 3×
“…efficiently package genomes up to ∼ 4.7 kb (51), this makes AAV vector well suited for both gene correction and transgene addition, whereas due to size limitations single strand oligonucleotides are best suited for gene correction or insertion of small DNA fragments as described previously (16,17).”
InfluentialMechanism of homologous recombination: mediators and helicases take on regulatory functions
Sung, P., & Klein, H. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2008 · Cited by 700 · cited 1×
“Repair of DSBs can proceed via the non-homologous end joining (NHEJ) or homology-directed repair (HDR) pathways (9,10).”
Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity
Braun, C. J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., Modlich, U., Beier, R., Göhring, G., Steinemann, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007280 · Cited by 562
The pharmacology of second-generation chimeric antigen receptors
van der Stegen, S. J. C., Hamieh, M., & Sadelain, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4597 · Cited by 555
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Self-citationAn unbiased genome-wide analysis of zinc-finger nuclease specificity
Gabriel, R., Lombardo, A., Arens, A., Miller, J. C., Genovese, P., Kaeppel, C., Nowrouzi, A., Bartholomae, C. C., Wang, J., Friedman, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1948 · Cited by 526 · cited 1×
“Indel events in aligned sequences were defined as described previously (25), with the exceptions that indels of 1 bp in length were also considered true indels to avoid undercounting real events, and true indels must include deletions occurring within the sequence spanning between the penultimate bases (adjacent to th…”
Self-citationSelf-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515 · cited 2×
“However, comparable peak levels of HDR between cells treated with either single-strand or self-complementary (double-stranded) AAV (51) donor vector (Supplementary Figure S12) do not support such a hypothesis.”
InfluentialHigh-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases
Chen, F., Pruett-Miller, S. M., Huang, Y., Gjoka, M., Duda, K., Taunton, J., Collingwood, T. N., Frodin, M., & Davis, G. D. (2011) · Nature Methods · doi:10.1038/nmeth.1653 · Cited by 474 · cited 4×
“…efficiently package genomes up to ∼ 4.7 kb (51), this makes AAV vector well suited for both gene correction and transgene addition, whereas due to size limitations single strand oligonucleotides are best suited for gene correction or insertion of small DNA fragments as described previously (16,17).”
InfluentialNaive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma
Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E.-K. M., Muranski, P., Restifo, N. P., & Antony, P. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091921 · Cited by 457
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448 · cited 1×
“For example, disruption of genes in T cells that play a role in suppression of effector activity, such as programmed cell death 1 (PDCD1, also known as PD1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and others, to make genetic engineered T cells less susceptible to the immune evasion mechanisms of tumor ce…”
Self-citationEnhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures
Doyon, Y., Vo, T. D., Mendel, M. C., Greenberg, S. G., Wang, J., Xia, D. F., Miller, J. C., Urnov, F. D., Gregory, P. D., & Holmes, M. C. (2011) · Nature Methods · doi:10.1038/nmeth.1539 · Cited by 402 · cited 8×
“ZFNs targeting the CCR5 and AAVS1 loci have been described previously (11,13).”
InfluentialSelf-citationYuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Boczkowski, D., Nair, S. K., Nam, J., Lyerly, H. K., & Gilboa, E. (2000) · PubMed · Cited by 343
Site-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo, A., Cesana, D., Genovese, P., Di Stefano, B., Provasi, E., Colombo, D. F., Neri, M., Magnani, Z., Cantore, A., Lo Riso, P., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1674 · Cited by 331 · cited 4×
“CCR5 and AAVS1 homologous donor templates (12,22) were cloned into a customized plasmid pRS165 derived from pAAV-MCS (Agilent Technologies, Santa Clara, CA, USA), containing AAV2 inverted terminal repeats (ITRs), to enable packaging as AAV vectors us-ing the triple-transfection method (23).”
InfluentialSelf-citationToward eliminating HLA class I expression to generate universal cells from allogeneic donors
Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C., Zhou, Y., Crossland, D. L., Huls, H., Littman, N., Zhang, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-03-478255 · Cited by 311 · cited 1×
“For example, disruption of genes in T cells that play a role in suppression of effector activity, such as programmed cell death 1 (PDCD1, also known as PD1), cytotoxic T-lymphocyte-associated protein 4 (CTLA4), and others, to make genetic engineered T cells less susceptible to the immune evasion mechanisms of tumor ce…”
Self-citationDeKelver, R. C., Choi, V. M., Moehle, E. A., Paschon, D. E., Hockemeyer, D., Meijsing, S. H., Sancak, Y., Cui, X., Steine, E. J., Miller, J. C., et al. (2010) · Genome Research · doi:10.1101/gr.106773.110 · Cited by 307 · cited 13×
“ZFNs targeting the CCR5 and AAVS1 loci have been described previously (11,13).”
InfluentialSelf-citationGene Conversion Tracts from Double-Strand Break Repair in Mammalian Cells
Elliott, B., Richardson, C., Winderbaum, J., Nickoloff, J. A., & Jasin, M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.93 · Cited by 304 · cited 1×
“The size and position of the homology arms is especially important if the intended target site for gene correction or transgene addition is distant from the nuclease cleavage site, as this can lead to substantially reduced levels of HDR-mediated genome editing (48– 50).”
Adeno-associated virus vectors preferentially transduce cells in S phase.
Russell, D. W., Miller, A. D., & Alexander, I. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8915 · Cited by 275 · cited 1×
“In this regard, AAV preferentially transduce cells in S phase (52).”
Adeno-associated virus vectors integrate at chromosome breakage sites
Miller, D. G., Petek, L. M., & Russell, D. W. (2004) · Nature Genetics · doi:10.1038/ng1380 · Cited by 266 · cited 1×
“In addition to engaging the homology-directed repair pathways to achieve precise on-target genome editing, AAV genomes can also become inserted at the site of a DSB through NHEJ-mediated end capture events (45–47).”
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264 · cited 1×
“Nucleic Acids Research, 2016, Vol. 44, No. 3 e30 CD8 + cytotoxic T lymphocytes (CTLs) have been proven to exhibit potent anti-tumor activity in preclinical and clinical studies (1–2 , 26– 28 ).”
Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme
Wang, J., Friedman, G., Doyon, Y., Wang, N. S., Li, C. J., Miller, J. C., Hua, K. L., Yan, J. J., Babiarz, J. E., Gregory, P. D., et al. (2012) · Genome Research · doi:10.1101/gr.122879.111 · Cited by 135 · cited 2×
“CCR5 and AAVS1 homologous donor templates (12,22) were cloned into a customized plasmid pRS165 derived from pAAV-MCS (Agilent Technologies, Santa Clara, CA, USA), containing AAV2 inverted terminal repeats (ITRs), to enable packaging as AAV vectors us-ing the triple-transfection method (23).”
Self-citationDonor DNA Utilization During Gene Targeting with Zinc-Finger Nucleases
Beumer, K. J., Trautman, J. K., Mukherjee, K., & Carroll, D. (2013) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.112.005439 · Cited by 127
Mock, U., Machowicz, R., Hauber, I., Horn, S., Abramowski, P., Berdien, B., Hauber, J., & Fehse, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv469 · Cited by 126 · cited 1×
“Delivery of ZFN as mRNA by electroporation appears to be very efficient with minimal cytotoxicity (14,16).”
Mechanisms of Retroviral Integration and Mutagenesis
Cavazza, A., Moiani, A., & Mavilio, F. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.203 · Cited by 125 · cited 1×
“However, the semi-random nature of vector insertion can result in non-authentic patterns of gene expression, transgene silencing over time, or the potential to trans-activate neighboring genes leading to insertional mutagenesis events (5–7).”
Capture of DNA Sequences at Double-Strand Breaks in Mammalian Chromosomes
Lin, Y., & Waldman, A. S. (2001) · Genetics · doi:10.1093/genetics/158.4.1665 · Cited by 113
Promiscuous patching of broken chromosomes in mammalian cells with extrachromosomal DNA
Lin, Y., & Waldman, A. S. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.19.3975 · Cited by 53
A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy
Chung, D., Shin, H.-J., & Hong, Y.-K. (2014) · Journal of Immunology Research · doi:10.1155/2014/326545 · Cited by 36
Genome engineering with TALENs and ZFNs: Repair pathways and donor design
Carroll, D., & Beumer, K. J. (2014) · Methods · doi:10.1016/j.ymeth.2014.03.026 · Cited by 35 · cited 1×
“The size and position of the homology arms is especially important if the intended target site for gene correction or transgene addition is distant from the nuclease cleavage site, as this can lead to substantially reduced levels of HDR-mediated genome editing (48– 50).”
Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma
Hodi, F. S., & Fisher, D. E. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1259 · Cited by 11
“Model T” Cells: A Time-Tested Vehicle for Gene Therapy
Kerkar, S. P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00304 · Cited by 9 · cited 1×
“…transgenes can be introduced into T cells to generate effector and memory CD8 and CD4 T lymphocytes specific for viral, fungal, bacterial, parasitic, and tumor-antigens and to design regulatory lymphocytes specific for the self-antigens responsible for autoimmune and inflammatory diseases (4).”
Cited by
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
“Co-delivery Co-delivery of Cas9 mRNA and sgRNA or ZFN mRNA for ex vivo gene editing can be achieved via physical methods that bypass the extracellular and cytoplasmic barriers to deposit the molecular cargoes, such as electroporation 145,146 or microinjection into embryos.”
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Metadata
- Authors
- Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C.
- Affiliations
- Sangamo BioSciences (United States) (US)
- Corresponding author
- Wang, Jianbin
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-02
- Volume
- 44
- Issue
- 3
- Pages
- e30-e30
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC4756813
- OpenAlex
- W1909557371
- Semantic Scholar
- 9f6bb7afb7fabc85e007197bcf8398372df2e5ee
- Cited by
- 128
- References
- 54
- Citations by year
- 2026: 11 · 2025: 2 · 2024: 7 · 2023: 14 · 2022: 13 · 2021: 14 · 2020: 11 · 2019: 18 · 2018: 16 · 2017: 13 · 2016: 9
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nucleic Acids Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- genome editing, human T cells, zinc finger nucleases, AAV6 vector, homology-directed repair, CCR5, AAVS1 safe harbor, CD8+ T cells, CD4+ T cells, gene correction, adoptive T cell therapy, T cell engineering
- MeSH terms
- Dependovirus, Endonucleases, Genetic Vectors, Humans, RNA, Messenger, Transfection, CD4-Positive T-Lymphocytes, Genome, Human, Zinc Fingers, CD8-Positive T-Lymphocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.